SEC 13F Intelligence

Checkpoint Capital L.P. / PTGX

Checkpoint Capital L.P.’s Protagonist Therapeutics Inc Position

Does Checkpoint Capital L.P. own Protagonist Therapeutics Inc (PTGX)? Not currently — the last reported position was 81.3K shares worth $4M in Q2 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$4M
Q2 2025
Shares
81.3K
% of Portfolio
+2.09%
Quarters Held
6
position exited

Position History PTGX

Reported value by quarter
Q4 ’23: $6MQ4 ’23Q1 ’24: $8MQ1 ’24Q2 ’24: $12MQ2 ’24Q3 ’24: $11MQ3 ’24Q1 ’25: $8MQ1 ’25Q2 ’25: $4MQ2 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q2 202581.3K$4M+2.09%
Q1 2025175.2K$8M+4.65%
Q3 2024240.0K$11M+5.36%
Q2 2024355.0K$12M+7.42%
Q1 2024280.3K$8M+5.42%
Q4 2023266.9K$6M+3.71%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Checkpoint Capital L.P.’s full portfolio or all institutional holders of PTGX.